Results 241 to 250 of about 20,950 (257)

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

Gut, 2012
Bruce E Sands, Marc Vandemeulebroecke, Peter D R Higgins   +2 more
exaly  

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

Lancet, The, 2015
Philip J Mease, Bruce W Kirkham, Arthur Kavanaugh   +2 more
exaly  

Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial

Lancet, The, 2013
Xenofon Baraliakos, Juergen Braun, Joachim Sieper   +2 more
exaly  

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial

Journal of the American Academy of Dermatology, 2015
Andrew Blauvelt, Kristian Reich, T-F Tsai   +2 more
exaly  

Secukinumab is not associated with cancer recurrence or progression in patients with spondyloarthritis and history of neoplastic disease

Rheumatology International
N. Farina, A. Tomelleri, N. Boffini, A. Cariddi, S. Calvisi, E. Baldissera, M. Matucci-Cerinic, L. Dagna   +7 more
semanticscholar   +1 more source

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis

New England Journal of Medicine, 2015
Joachim Sieper, Juergen Braun, Xenofon Baraliakos   +2 more
exaly  

Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial

The Lancet, 2020
I. McInnes, F. Behrens, P. Mease, A. Kavanaugh, C. Ritchlin, P. Nash, J. G. Masmitjá, P. Goupille, T. Korotaeva, A. Gottlieb, R. Martin, K. Ding, P. Pellet, S. Mpofu, L. Pricop   +14 more
semanticscholar   +1 more source

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis

New England Journal of Medicine, 2015
Philip J Mease, Bruce W Kirkham, Arthur Kavanaugh   +2 more
exaly  

Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis

Journal of the American Academy of Dermatology, 2016
Peter C M Van De Kerkhof, Christopher Em Griffiths, Kristian Reich   +2 more
exaly  

Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double‐Blind, Active Comparator– and Placebo‐Controlled Study

Arthritis and Rheumatology, 2017
Francisco J Blanco Garcia
exaly